Physicians

Department / Division
Medicine / Medicine - Oncology

Address
P.O. Box 2736
Durham, NC 27705

Appointment Telephone
919-668-6688

Office Telephone
919-681-1604

Fax Telephone
919-681-7488

Training

• MD, University at Buffalo SUNY School of Medicine & Biomedical Sciences, 1972

Residency

• Internal Medicine, UNC Hospitals, 1972-1974

Fellowship

• Hematology/Oncology, Roswell Park Memorial Institute (New York), 1975-1977

Other Training

• MPH, Biostatistics, Harvard University (Massachusetts), 1982

Clinical Interests
Clinical investigation; experimental therapeutics; breast cancer; care of patients with breast cancer, with a focus on managing early-stage patients for staging/prognostic evaluation and clinical decision making; comparative effectiveness and outcomes research

Research Interests
Dr. Gary Lyman is Professor of Medicine in the Division of Medical Oncology, Department of Internal Medicine at Duke University School of Medicine and the Duke Cancer Institute. He serves as Director of the Comparative Effectiveness and Outcomes Research Program in Oncology.  Dr Lyman is also Senior Fellow in the Duke Center for Clinical Health Policy Research. He is a nationally and internationally recognized authority on comparative effectiveness and health services and outcomes research. Lyman research is funded by the National Cancer Institute, the National Heart Lung and Blood Institute, the American Society of Clinical Oncology along with industry grants related to supportive cancer care. Dr Lyman has published some 400 research articles in in the professional medical literature. Direct funding from all sources supports an annual Comparative Effectiveness and Outcomes Research budget of over $5 million.

Dr Lyman’s research interests include:
Personalized Medicine and Cancer Supportive Care:  In addition to the conduct of randomized controlled trials of new cancer diagnostic, prognostic, treatment and supportive care approaches, Dr Lyman’s research interests include the personalized management of early-stage breast cancer and supportive care of patients receiving cancer chemotherapy, most notably those at risk for febrile neutropenia and venous thromboembolism. Based on clinical trial results, Dr Lyman is actively involved in the development and validation of clinical risk models for patient selection and targeted intervention and preventive strategies. Dr Lyman is co-PI on an NCI on comparative effectiveness of cancer pharmacogenomics grant to discover and validate new genomic tools for guiding more personalized cancer treatments and on an NHLBI trial of thromboprophylaxis in high risk ambulatory patients receiving cancer chemotherapy.

Evidence synthesis, clinical practice guidelines and health policy: Dr Lyman conducts systematic reviews and meta-analyses of major clinical issues in support of clinical practice guidelines. Dr Lyman chairs several guidelines for the American Society of Clinical Oncology including those on antiemetics, venous thromboembolism, sentinel node biopsy in patients with breast cancer and cutaneous melanoma and on weight based dosing of chemotherapy. Dr Lyman also conducts analyses of large population studies of clinical outcomes associated with of current cancer patient management in a real world setting with a particular focus on cancer management in the elderly patient with cancer. Dr Lyman leads several decision simulation studies for improved clinical decision making and cost-effectiveness analysis of new and novel therapies based on results of clinical trials, systematic reviews and population studies. He serves as an advisor on new oncologic agents to the US FDA. Dr Lyman also serves as Editor-in-Chief of Cancer Investigation and on the editorial boards of several prestigious research journals.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Amgen, Inc.
• Genomic Health, Inc.
• Proventys, Inc.

Representative Publications
Griffiths RI, Barron RL, Gleeson ML, Danese MD, O'Hagan A, Chia VM, Legg JC, Lyman GH. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. Pharmacoeconomics. 2012 Feb 1;30(2):103-18. (2012) Abstract

Hurwitz HI, Lyman GH. Registries and Randomized Trials in Assessing the Effects of Bevacizumab in Colorectal Cancer: Is There a Common Theme? J Clin Oncol. 2012 Jan 17. (2012) Abstract

Weycker D, Barron R, Edelsberg J, Kartashov A, Lyman GH. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat. 2012 Jan 24. (2012) Abstract

Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, . 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011 Jan;47(1):8-32. (2011) Abstract

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH. Antiemetics: american society of clinical oncology clinical practice guideline update. J Clin Oncol. 2011 Nov 1;29(31):4189-98. (2011) Abstract

Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M. Myeloid growth factors. J Natl Compr Canc Netw. 2011 Aug 1;9(8):914-32. (2011) Abstract

Eldar-Lissai A, Lyman GH. The economics of the hematopoietic growth factors. Cancer Treat Res. 2011;157:403-18. (2011) Abstract

Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, Defelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ 3rd, Balducci L. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2011 Nov 9. (2011) Abstract

Hirsch BR, Lyman GH. Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw. 2011 Aug 1;9(8):934-43. (2011) Abstract

Hirsch BR, Lyman GH. Breast cancer screening with mammography. Curr Oncol Rep. 2011 Feb;13(1):63-70. (2011) Abstract

Hurwitz HI, Saltz LB, Van Cutsem E, Cassidy J, Wiedemann J, Sirzén F, Lyman GH, Rohr UP. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011 May 1;29(13):1757-64. (2011) Abstract

Kuderer NM, Lyman GH. Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst. 2011 Jun 22;103(12):910-3. (2011) Abstract

Lyman GH, Barron RL, Natoli JL, Miller RM. Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. Crit Rev Oncol Hematol. 2011 May 31. (2011) Abstract

Lyman GH, Dale DC. Introduction to the hematopoietic growth factors. Cancer Treat Res. 2011;157:3-10. (2011) Abstract

Lyman GH, Dale DC. Long-term outcomes of myeloid growth factor treatment. J Natl Compr Canc Netw. 2011 Aug 1;9(8):945-52. (2011) Abstract

Lyman GH, Kleiner JM. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. Cancer Treat Res. 2011;157:145-65. (2011) Abstract

Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011 May 1;117(9):1917-27. (2011) Abstract

Lyman GH, Kuderer NM. Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome. Cancer Treat Res. 2011;157:167-78. (2011) Abstract

Lyman GH. Chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines.  J Oncol Pract.  2011 Jan;7(1):17-8. (2011) Abstract

Lyman GH. The myeloid growth factors. Cancer Treat Res. 2011;157:109-25. (2011) Abstract

Lyman GH. Venous thromboembolism in the patient with cancer: Focus on burden of disease and benefits of thromboprophylaxis. Cancer. 2011 Apr 1;117(7):1334-49. (2011) Abstract

Rajan SS, Lyman GH, Carpenter WR, Stearns SC. Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. Breast Cancer Res Treat. 2011 Jun;127(2):511-20. (2011) Abstract

Rajan SS, Lyman GH, Stearns SC, Carpenter WR. Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. Med Care. 2011 Jul;49(7):649-57. (2011) Abstract

Rajan SS, Stearns SC, Lyman GH, Carpenter WR. Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Res Treat. 2011 Nov;130(1):255-66. (2011) Abstract

Valsecchi ME, Silbermins D, de Rosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011 Apr 10;29(11):1479-87. (2011) Abstract

Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, Demartino J, Larsen JK, Hoffman JM. NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives. J Natl Compr Canc Netw. 2011 Sep;9 Suppl 4:S1-S22. (2011) Abstract

Zeliadt SB, Sekaran NK, Hu EY, Slatore CC, Au DH, Backhus L, Wu DY, Crawford J, Lyman GH, Dale DC. Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest. J Thorac Oncol. 2011 Oct;6(10):1726-32. (2011) Abstract

de Rosa N, Lyman GH, Silbermins D, Valsecchi ME, Pruitt SK, Tyler DM, Lee WT. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg. 2011 Sep;145(3):375-82. (2011) Abstract

Aapro M, Schwenkglenks M, Lyman GH, Lopez Pousa A, Lawrinson S, Skacel T, Bacon P, von Minckwitz G. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol. 2010 Jun;74(3):203-10. (2010) Abstract

Connolly GC, Khorana AA, Kuderer NM, Culakova E, Francis CW, Lyman GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res. 2010 Aug;126(2):113-8. (2010) Abstract

Hamilton EP, Lyman GH, Peppercorn J. Availability of experimental therapy outside oncology randomized clinical trials in the United States. J Clin Oncol. 2010 Dec 1;28(34):5067-73. (2010) Abstract

Herold CI, Djulbegovic B, Hozo I, Lyman GH. Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Res Treat. 2010 Jun;121(3):771-6. (2010) Abstract

Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM, Crawford J. Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review. J Clin Oncol. 2010 Jun 10;28(17):2914-2924. (2010) Abstract

Lyman GH, Hirsch B: Comparative Effectiveness Research and Genomic Personalized Medicine. Personalized Medicine 2010: 7: 223-227. (2010)

Lyman GH, Kuderer NM. Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. Thromb Res. 2010 Apr;125 Suppl 2:S120-7. (2010) Abstract

Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010 Dec 1;116(23):5555-63. (2010) Abstract

Lyman GH, Rolston KV. How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract. 2010 May;6(3):149-52. (2010) Abstract

Lyman GH. A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. Curr Opin Hematol. 2010 Oct 29. (2010) Abstract

Lyman GH. Anthracyclines in the treatment of early-stage breast cancer: ally or adversary? Cancer Invest. 2010 Mar;28(3):217-9. (2010) Abstract

Lyman GH. Breast cancer screening: science, society and common sense. Cancer Invest. 2010 Jan;28(1):1-6. (2010) Abstract

Lyman GH: Comparative Effectiveness Research in Oncology. ASCO Education Book; 2010; 211-215. (2010)

Schwenkglenks M, Pettengell R, Szucs TD, Culakova E, Lyman GH. Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. J Hematol Oncol. 2010 Aug 19;3(1):27. (2010) Abstract

Tang P, Wang J, Hicks DG, Wang X, Schiffhauer L, McMahon L, Yang Q, Shayne M, Huston A, Skinner KA, Griggs J, Lyman G. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest. 2010 Nov;28(9):978-82. (2010) Abstract

Balaban EP, Brouwers MC, Lyman GH: Issues in Clinical Practice Guideline Implementation and Utilization. ASCO Education Book, 2009; 338-344. (2009)

Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yaneeklov T. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis. J Natl Compr Canc Netw. 2009 Nov;7(10):1060-96. (2009) Abstract

Cosler LE, Lyman GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest. 2009 Dec;27(10):953-9. (2009) Abstract

Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK. Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan;7(1):64-83. (2009) Abstract

Khorana AA, Lyman GH: Incidence and Prevention of Cancer-Associated Thrombosis. ASCO Education Book; 2009; 321-325. (2009)

Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009 Oct 10;27(29):4919-26. (2009) Abstract

Kuderer NM, Lyman GH. Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer. Cancer Invest. 2009 Nov;27(9):885-90. (2009) Abstract

Lyman G, Lalla A, Barron R, Dubois RW. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009 Feb;25(2):401-11. (2009) Abstract

Lyman GH (ed): The Oxford American Handbook of Oncology, Oxford University Press 2009; New York, NY pp 829. (2009)

Lyman GH, Khorana AA, Kuderer NM, Lee AY. Cancer and thrombosis: back to the future renewed interest in an old problem. Cancer Invest. 2009 Jun;27(5):472-3. (2009) Abstract

Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009 Oct 10;27(29):4821-6. (2009) Abstract

Lyman GH, Kuderer NM, Freedland SJ. Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding. J Natl Cancer Inst. 2009 Apr 15;101(8):543-5. (2009) Abstract

Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states. Clin Ther. 2009 May;31(5):1092-104. (2009) Abstract

Lyman GH, Peppercorn J. Isolated tumor cells in breast cancer.  N Engl J Med.  2009 Nov 12;361(20):1994-6. (2009) Abstract

Lyman GH, Van Zee KJ, Edge SB: Impact and Remaining Challenges in the Use of Sentinel Node Biopsy in Early-Stage Breast Cancer. ASCO Education Book, 2009; 346-353. (2009)

Lyman GH. Comparative effectiveness research in oncology: the need for clarity, transparency and vision. Cancer Invest. 2009 Jul;27(6):593-7. (2009) Abstract

Lyman GH. Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes. J Natl Compr Canc Netw. 2009 Jan;7(1):99-108. (2009) Abstract

Lyman GH. Preventing venous thromboembolism in cancer patients: can we do better? J Oncol Pract. 2009 Jul;5(4):165-6. (2009) Abstract

Lyman GH. The road to romiplostim approval and beyond. Oncology (Williston Park). 2009 Jul;23(8):709-10, 715. (2009) Abstract

Lyman GH. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer. 2009 Dec 15;115(24):5637-50. (2009) Abstract

Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson JJ, Long SR, Knopf J, Lyman GH, Messing EM. Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine?: the use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 2009 Jun 15;115(12):2660-70. (2009) Abstract

Shayne M, Culakova E, Wolff D, Poniewierski MS, Dale DC, Crawford J, Lyman GH. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer. 2009 Nov 15;115(22):5319-28. (2009) Abstract

von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer. 2009 Mar;45(4):608-17. (2009) Abstract

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008 Apr 2;299(13):1574-87. (2008) Abstract

Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG, Basu SK, Kun LE, Ng A, Mauch P, Sandhu A, Culakova E, Lyman G, Mendenhall N. Subsequent Malignancies in Children Treated for Hodgkin's Disease: Associations With Gender and Radiation Dose. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):24-33. (2008) Abstract

Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008 Feb;6(2):109-18. (2008) Abstract

Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008 Mar-Apr;11(2):172-9. (2008) Abstract

Falanga A, Lee AYY, Streiff MB, Lyman GH: Cancer and Thrombosis 3: Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer. ASCO Education Book, 2008: 258-268. (2008)

Ferro SA, Myer BS, Wolff DA, Poniewierski MS, Culakova E, Cosler LE, Scarpace SL, Khorana AA, Lyman GH. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care. 2008 Nov;14(11):717-25. (2008) Abstract

Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008 Mar;49(3):480-508. (2008) Abstract

Francis CW, Kakkar AK, Levine MN, Lyman GH: Cancer and Thrombosis 2: Prevention of Venous Thromboembolism in Cancer Patients. ASCO Education Book, 2008 250-256. (2008)

Greenberg PL, Cosler LE, Ferro SA, Lyman GH. The costs of drugs used to treat myelodysplastic syndromes following national comprehensive cancer network guidelines. J Natl Compr Canc Netw. 2008 Oct;6(9):942-53. (2008) Abstract

Hanley K, Wang J, Bourne P, Yang Q, Gao AC, Lyman G, Tang P. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol. 2008 Mar;39(3):386-92. (2008) Abstract

Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y, Becton D, Smith FO, Woods WG, . Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol. 2008 Dec 10;26(35):5797-801. (2008) Abstract

Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008 Nov 24;168(21):2377-81. (2008) Abstract

Khorana AA, Francis CW, Lyman GH. Reply to frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2008 Jul 1;113(1):224. (2008) Abstract

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15;111(10):4902-7. (2008) Abstract

Khorana AA, Liebman H, White RH, Wun T, Lyman GH: Cancer and Thrombosis 1:The Risk of Venous Thromboembolism in Cancer Patients. ASCO Education Book, 2008: 240-248. (2008)

Lyman GH, Crawford J (eds): Cancer Supportive Care: Advances in Therapeutic Strategies, Informa Healthcare, New York 2008; pp395. (2008)

Lyman GH, Glaspy J: Early Intervention with rhu Erythropoietin for Chemotherapy-Induced Anemia. In Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology – Scientific and Clinical Aspects of Anemia in Cancer, 2nd edition, Springer-Verlag, Wien, New York, 2008: 509-530. (2008)

Lyman GH, Hauser RS. Optimal cancer care across the spectrum of life and disease. Am J Manag Care. 2008 May;14(5):262-4. (2008) Abstract

Lyman GH. ASCO Clinical Practice Guidelines: Past, Present and Future. J Oncol Pract. 2008 Sep;4(5):236-7. (2008) Abstract

Lyman GH. Caring for the elderly cancer patient: training the next generation of oncologists. J Oncol Pract. 2008 Jul;4(4):193-4. (2008) Abstract

Lyman GH. Undertreatment of cancer patients with chemotherapy is a global concern. J Oncol Pract. 2008 May;4(3):114-5. (2008) Abstract

Ramsey SD, Liu Z, Boer R, Sullivan SD, Malin J, Doan QV, Dubois RW, Lyman GH. Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy. Value Health. 2008 Jul 31. (2008) Abstract

Somerfield MR, Einhaus K, Hagerty KL, Brouwers MC, Seidenfeld J, Lyman GH, . American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol. 2008 Aug 20;26(24):4022-6. (2008) Abstract

Blumberg N, Zhao H, Wang H, Messing S, Heal JM, Lyman GH. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients.  Transfusion.  2007 Apr;47(4):573-81. (2007) Abstract

Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics. 2007;25(4):343-51. (2007) Abstract

Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Heaney ML, Htoy S, Kloth DD, Lyman GH, Messersmith WA, Michaud LB, Miyata SC, Robbins A, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK, . Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb;5(2):188-202. (2007) Abstract

Djulbegovic B, Hozo I, Lyman GH. Estimating net benefits and harms of screening mammography in women age 40 to 49 years. Ann Intern Med. 2007 Dec 18;147(12):882. (2007) Abstract

Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA, Crawford J, Dale DC, Lyman GH. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007 Jun 20;25(18):2522-7. (2007) Abstract

Griggs JJ, Culakova E, Sorbero ME, van Ryn M, Poniewierski MS, Wolff DA, Crawford J, Dale DC, Lyman GH. Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol. 2007 Jan 20;25(3):277-84. (2007) Abstract

Huston A, Lyman GH. Agents under investigation for the treatment and prevention of neutropenia. Expert Opin Investig Drugs. 2007 Nov;16(11):1831-40. (2007) Abstract

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007 Nov 15;110(10):2339-46. (2007) Abstract

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007 Mar;5(3):632-4. (2007) Abstract

Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007 Jul 20;25(21):3158-67. (2007) Abstract

Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007 Sep 1;110(5):1149-61. (2007) Abstract

Lyman GH, Burstein H (eds): Translational Therapeutic Strategies in Breast Cancer, Informa Healthcare, New York 2007; pp 321. (2007)

Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007 Mar 15;109(6):1011-8. (2007) Abstract

Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. J Clin Oncol. 2007 Oct 29. (2007) Abstract

Lyman GH, Kleiner JM. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. J Natl Compr Canc Netw. 2007 Feb;5(2):217-28. (2007) Abstract

Lyman GH, Kuderer NM: Improving outcomes from cancer-associated VTE: lessons from the ASCO guidelines in Cancer Associated Thrombosis, Khorana A, Francis CF, (eds): Informa Healthcare, New York 2007 (2007)

Lyman GH, Shayne M. Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol. 2007 Jul;19(4):299-307. (2007) Abstract

Lyman GH. ASCO Clinical Practice Guidelines and Beyond. J Oncol Pract. 2007 Nov;3(6):330-1. (2007) Abstract

Lyman GH. Economics of cancer care. J Oncol Pract. 2007 May;3(3):113-4. (2007) Abstract

Lyman GH. Editorial: gene expression profile assays as an aid in treatment decision making in early-stage breast cancer. J Oncol Pract. 2007 Jul;3(4):187-8. (2007) Abstract

Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007 Aug 10. (2007) Abstract

Shayne M, Culakova E, Poniewierski MS, Wolff D, Dale DC, Crawford J, Lyman GH. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007 Oct 1;110(7):1611-20. (2007) Abstract

Tang P, Hajdu SI, Lyman GH. Ductal carcinoma in situ: a review of recent advances. Curr Opin Obstet Gynecol. 2007 Feb;19(1):63-7. (2007) Abstract